POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER
Details
- Status
- Prescription
- First Approved
- 1989-12-26
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER Approval History
What POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER Treats
2 indicationsPOTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER is approved for 2 conditions since its original approval in 1989. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypokalemia
- Metabolic Alkalosis
Drugs Similar to POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER FDA Label Details
ProIndications & Usage
FDA Label (PDF)Potassium Chloride Extended-Release Tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium Chloride Extended-Release Tablets are a potassium salt, indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.